Compare Brigit Biofarmaka Teknologi Tbk. (OBAT) vs Solusi Bangun Indonesia Tbk. (SMCB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brigit Biofarmaka Teknologi Tbk. vs Solusi Bangun Indonesia Tbk. — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp240 (market cap 166.01B, 324K 24h volume), while Solusi Bangun Indonesia Tbk. trades at Rp775 (market cap 6.99T). The key difference: Solusi Bangun Indonesia Tbk. is far larger — about 42.1× Brigit Biofarmaka Teknologi Tbk.'s market cap. Which is the better fit depends on your goals.
| OBAT | SMCB | |
|---|---|---|
Market Cap | 166.01B | 6.99T |
Volume | 324K | — |
Lot | 3.24K | — |
Turnover | 77.68M | — |
Average Price | 239.75 | — |
Value | 77.68M | — |
Indicative Equilibrium Price | 240 | — |
Indicative Equilibrium Volume | 1 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →About Solusi Bangun Indonesia Tbk.
PT Holcim Indonesia Tbk (the Company) was originally a joint venture between a subsidiary of Kaiser Cement and Gypsum Corp. and PT Semen Gresik. Founded in 1971, the company owns a factory in Narogong, West Java, with an annual capacity of 3 million tons. The Company changed its foreign capital investment status (PMA) to domestic capital investment (PMDN) based on the approval from Chairman of Capital Investment Coordinating Board No. 17/V/1988 dated November 19, 1988. Effective January 1, 2006, the Company changed its name from PT Semen Cibinong Tbk. to PT Holcim Indonesia Tbk.
Read more on SMCB →
